Penserra Capital Management LLC acquired a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 19,112 shares of the company's stock, valued at approximately $2,229,000.
Other hedge funds also recently modified their holdings of the company. NBC Securities Inc. acquired a new stake in shares of Axsome Therapeutics during the first quarter worth approximately $31,000. Raiffeisen Bank International AG bought a new stake in shares of Axsome Therapeutics during the fourth quarter valued at approximately $51,000. Assetmark Inc. bought a new stake in shares of Axsome Therapeutics during the fourth quarter valued at approximately $52,000. Aquatic Capital Management LLC bought a new stake in shares of Axsome Therapeutics during the fourth quarter valued at approximately $76,000. Finally, GF Fund Management CO. LTD. bought a new stake in shares of Axsome Therapeutics during the fourth quarter valued at approximately $86,000. Institutional investors and hedge funds own 81.49% of the company's stock.
Wall Street Analyst Weigh In
AXSM has been the topic of several research analyst reports. HC Wainwright reissued a "buy" rating and set a $180.00 price target on shares of Axsome Therapeutics in a research note on Tuesday, June 10th. Mizuho increased their price target on shares of Axsome Therapeutics from $212.00 to $216.00 and gave the company an "outperform" rating in a research note on Thursday, March 27th. Cantor Fitzgerald raised shares of Axsome Therapeutics to a "strong-buy" rating in a research note on Wednesday, May 14th. Jefferies Financial Group initiated coverage on shares of Axsome Therapeutics in a research note on Monday, April 7th. They set a "buy" rating and a $200.00 price target on the stock. Finally, Morgan Stanley initiated coverage on shares of Axsome Therapeutics in a research note on Thursday, July 3rd. They set an "overweight" rating and a $190.00 price target on the stock. One research analyst has rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $172.33.
Check Out Our Latest Research Report on AXSM
Insider Transactions at Axsome Therapeutics
In other news, Director Mark Coleman sold 3,750 shares of Axsome Therapeutics stock in a transaction on Tuesday, May 27th. The shares were sold at an average price of $105.47, for a total transaction of $395,512.50. Following the transaction, the director directly owned 50,387 shares of the company's stock, valued at $5,314,316.89. This trade represents a 6.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Mark L. Jacobson sold 25,000 shares of Axsome Therapeutics stock in a transaction on Monday, June 9th. The stock was sold at an average price of $110.44, for a total transaction of $2,761,000.00. Following the transaction, the chief operating officer directly owned 5,783 shares in the company, valued at approximately $638,674.52. This represents a 81.21% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 93,437 shares of company stock valued at $9,834,215 over the last three months. 22.40% of the stock is currently owned by corporate insiders.
Axsome Therapeutics Trading Up 4.6%
Shares of NASDAQ AXSM traded up $4.99 during midday trading on Wednesday, reaching $113.40. 105,577 shares of the stock were exchanged, compared to its average volume of 665,520. The business has a 50-day simple moving average of $106.61 and a two-hundred day simple moving average of $107.92. The company has a market capitalization of $5.58 billion, a price-to-earnings ratio of -19.58 and a beta of 0.46. Axsome Therapeutics, Inc. has a 12 month low of $72.21 and a 12 month high of $139.13. The company has a debt-to-equity ratio of 3.48, a current ratio of 2.03 and a quick ratio of 1.96.
Axsome Therapeutics Company Profile
(
Free Report)
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.
See Also

Before you consider Axsome Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.
While Axsome Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.